Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00693303 · ClinicalTrials.gov registry record · NA
Examining the Effectiveness of My Scrivener on Handwriting Legibility
A NA study, sponsored by Shenandoah University.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT00693303: Completed NA study, sponsored by Shenandoah University.
NCT00693303 is a NA study that has completed, run by Shenandoah University. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00693303, a NA study, has completed, sponsored by Shenandoah University.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study was to examine the changes in handwriting performance in elementary aged children who received handwriting training which included use of the My Scrivener stylus. Training on the My Scrivener stylus provided additional feedback to the children which is hypothesized to produce significant improvement.
Primary Outcome
This criterion-referenced tool measures a child's legibility and speed in grades one through six. The child writes letters and words, numerals, performs near point and far point copying, writes to dictation, and composes a sentence.
Interventions
- BEHAVIORAL Handwriting Training using My Scrivener
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-08 |
| Phase | NA |
What the finished NCT00693303 record still lists
NCT00693303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Handwriting Training using My Scrivener is the first listed.
NCT00693303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00693303 about?
NCT00693303 is a clinical study titled "Examining the Effectiveness of My Scrivener on Handwriting Legibility". The purpose of this study was to examine the changes in handwriting performance in elementary aged children who received handwriting training which included use of the My Scrivener stylus. Training on the My Scrivener stylus provided additional feedback to the children which is hypothesized to produ...
What is the current status of trial NCT00693303?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2008-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00693303?
The interventions under investigation include: Handwriting Training using My Scrivener (BEHAVIORAL).
Who is sponsoring clinical trial NCT00693303?
This trial is sponsored by Shenandoah University, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00693303's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia